Item 7.01 Regulation FD Disclosure.

On January 5, 2022, Edgewise Therapeutics, Inc. (the "Company") issued a press release announcing positive topline results from the Becker muscular dystrophy, or Phase 1b, portion of a first-in-human Phase 1 clinical trial assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of EDG-5506, an orally administered small molecule myosin inhibitor designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies such as Duchenne muscular dystrophy and Becker muscular dystrophy. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.



Exhibit No.    Description

  99.1           Press
               Release of
               Edgewise
               Therapeutics,
               Inc. dated
               January 5,
               2022  .
104            Cover Page
               Interactive
               Data File
               (embedded
               within the
               Inline XBRL
               documents)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses